18110-86-6
Chemical Structure
Nigakinone
- CAS No.: 18110-86-6
- Formula:C15H10N2O3
- Molecular Weight:266.25
IUPAC Name: 5-hydroxy-4-methoxy-6H-indolo[3,2,1-de][1,5]naphthyridin-6-one
InChIKey: PGFKZUOYIFDMQJ-UHFFFAOYSA-N
SMILES: O=C1N2C3=C(N=CC=C3C4=C2C=CC=C4)C(OC)=C1O
Biological Activity: Nigakinone is an orally active FXR agonist and NLRP3 inhibitor. Nigakinone suppresses bile acid-induced inflammation and cell damage, regulates the bile acid profile, and alleviates intestinal mucosal barrier injury. Nigakinone synergizes with Irinotecan (HY-16562) to inhibit the proliferation and migration of colorectal cancer cells as well as the growth of subcutaneous xenograft tumors. Nigakinone can be used in research related to ulcerative colitis and colorectal cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nigakinone | 99.95% | Nigakinone is an orally active FXR agonist and NLRP3 inhibitor. Nigakinone suppresses bile acid-induced inflammation and cell damage, regulates the bile acid profile, and alleviates intestinal mucosal barrier injury. Nigakinone synergizes with Irinotecan (HY-16562) to inhibit the proliferation and migration of colorectal cancer cells as well as the growth of subcutaneous xenograft tumors. Nigakinone can be used in research related to ulcerative colitis and colorectal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Liu F, et al. Nigakinone alleviates DSS-induced experimental colitis via regulating bile acid profile and FXR/NLRP3 signaling pathways. Phytotherapy research : PTR. 2023 Jan;37(1):15-34. [Content Brief]
- [2]. Zhang Y, et al. Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts. Biochemical pharmacology. 2026 Jul;249:117904. [Content Brief]
Keywords
